|
|
Volumn 12, Issue 8, 2001, Pages 1047-1048
|
|
ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CA 15-3 ANTIGEN;
CARCINOEMBRYONIC ANTIGEN;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
ESTROGEN;
ESTROGEN RECEPTOR;
ETOPOSIDE;
FLUOROURACIL;
GONADORELIN;
METHOTREXATE;
PROGESTERONE;
TAMOXIFEN;
TUMOR MARKER;
ADULT;
AGED;
ARTICLE;
BREAST BIOPSY;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PATIENT;
CANCER RADIOTHERAPY;
CANCER RISK;
CANCER STAGING;
CLINICAL PROTOCOL;
CONTROLLED STUDY;
EUROPEAN UNION;
FEMALE;
FOLLOW UP;
HEALTH CARE ORGANIZATION;
HORMONAL THERAPY;
HUMAN;
HUMAN TISSUE;
MAJOR CLINICAL STUDY;
MAMMOGRAPHY;
MASTECTOMY;
MEDICAL DOCUMENTATION;
MULTIMODALITY CANCER THERAPY;
PATIENT CARE;
PRIORITY JOURNAL;
RISK ASSESSMENT;
TREATMENT PLANNING;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
EUROPE;
FEMALE;
HUMANS;
NEOPLASM STAGING;
RISK ASSESSMENT;
|
|
EID: 0034835254
PISSN: 09237534
EISSN: None
Source Type: Journal
DOI: 10.1023/A:1017448816215 Document Type: Article |
|
Times cited : (28)
|
|
References (4)
|
